BridgeBio Pharma, Inc. (FRA:2CL)

Germany · Delayed Price · Currency is EUR

58.48

-2.10 (-3.47%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Identifying and Advancing Transformative Medicines to Treat Patients	221.90M	9.30M	77.65M	69.72M	8.25M
Identifying and Advancing Transformative Medicines to Treat Patients Growth	2285.27%	-88.02%	11.38%	745.14%	-79.66%
Total	221.90M	9.30M	77.65M	69.72M	8.25M
Total Growth	2285.27%	-88.02%	11.38%	745.14%	-79.66%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
United States	-	-	-	69.72M	8.25M
United States Growth	-	-	-	745.14%	-79.66%
Europe, Middle East, and Africa (EMEA)	132.03M	-	-	-	-
Asia-Pacific (APAC)	76.56M	1.35M	-	-	-
Asia-Pacific (APAC) Growth	5575.31%	-	-	-	-
North America	-	7.90M	76.79M	-	-
North America Growth	-	-89.72%	-	-	-
Total	208.59M	9.25M	76.79M	69.72M	8.25M
Total Growth	2155.69%	-87.96%	10.15%	745.14%	-79.66%

Source: S&P Global Market Intelligence.